08764600 · Active · incorporated 12 years, 8 months ago · Weybridge
Biotech Biotech & Life Sciences Drug Discovery Series B+
Antev is a clinical-stage biotech company developing Teverelix, a next-generation GnRH antagonist, for high cardiovascular risk prostate cancer patients.
See the complete cap table with every shareholder, founder tags, dilution across 44 share allotments, round-by-round fundraising history, and the full filing timeline — parsed from official Companies House documents.
Create a free account Sign inFree accounts open 3 companies in full detail — no card required.